WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H318897
CAS#: 157283-68-6
Description: Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin analog (or more specifically, an analog of prostaglandin F2α) that works by increasing the outflow of aqueous fluid from the eyes.
Hodoodo Cat#: H318897
Name: Travoprost
CAS#: 157283-68-6
Chemical Formula: C26H35F3O6
Exact Mass: 500.24
Molecular Weight: 500.548
Elemental Analysis: C, 62.39; H, 7.05; F, 11.39; O, 19.18
Synonym: Travoprost, AL-6221, Travatan, Travoprostin
IUPAC/Chemical Name: propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
InChi Key: MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChi Code: InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
SMILES Code: O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COC2=CC=CC(C(F)(F)F)=C2)[C@H](O)C[C@@H]1O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 500.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015 Apr 10;9:633-43. doi: 10.2147/OPTH.S61444. eCollection 2015. Review. PubMed PMID: 25914522; PubMed Central PMCID: PMC4401333.
2: Konstas AG, Quaranta L, Realini T. Overview of the [corrected] travoprost /timolol BAK-free fixed combination. Expert Opin Pharmacother. 2012 Apr;13(5):757-66. doi: 10.1517/14656566.2012.662485. Epub 2012 Feb 24. Review. Erratum in: Expert Opin Pharmacother. 2012 Jun;13(8):1221. PubMed PMID: 22360540.
3: Denis P. Travoprost/timolol fixed combination in the management of open-angle glaucoma: a clinical review. Expert Opin Pharmacother. 2011 Feb;12(3):463-71. doi: 10.1517/14656566.2011.551007. Review. PubMed PMID: 21254951.
4: Cheng JW, Xi GL, Wei RL, Cai JP, Li Y. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis. Curr Ther Res Clin Exp. 2009 Aug;70(4):335-50. doi: 10.1016/j.curtheres.2009.08.006. Review. PubMed PMID: 24683242; PubMed Central PMCID: PMC3967344.
5: Herceg M, Noecker R. Travoprost/timolol fixed combination. Expert Opin Pharmacother. 2008 Apr;9(6):1059-65. doi: 10.1517/14656566.9.6.1059. Review. PubMed PMID: 18377347.
6: Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging. 2006;23(7):587-97; discussion 598-9. Review. PubMed PMID: 16930087.
7: Waugh J, Jarvis B. Travoprost. Drugs Aging. 2002;19(6):465-71; discussion 472-3. Review. PubMed PMID: 12149052.
8: Whitson JT. Travoprost--a new prostaglandin analogue for the treatment of glaucoma. Expert Opin Pharmacother. 2002 Jul;3(7):965-77. Review. PubMed PMID: 12083996.
9: Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004%/timolol 0.5% fixed combination. Drugs Today (Barc). 2007 Feb;43(2):77-83. Review. PubMed PMID: 17353945.
10: Holmstrom S, Buchholz P, Walt J, Wickstrøm J, Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005 Nov;21(11):1875-83. Review. PubMed PMID: 16307709.
11: Al-Jazzaf AM, DeSantis L, Netland PA. Travoprost: a potent ocular hypotensive agent. Drugs Today (Barc). 2003 Jan;39(1):61-74. Review. PubMed PMID: 12669109.
12: Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S105-15. Review. PubMed PMID: 12204706.